Lexapro is owned by Allergan.
Lexapro contains Escitalopram Oxalate.
Lexapro has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Lexapro are:
Lexapro was authorised for market use on 14 August, 2002.
Lexapro is available in tablet;oral dosage forms.
The generics of Lexapro are possible to be released after 12 February, 2023.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6916941 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(9 months ago) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7420069 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(9 months ago) | |
US6916941 (Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(3 months ago) | |
US7420069 (Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(3 months ago) |
Drugs and Companies using ESCITALOPRAM OXALATE ingredient
Market Authorisation Date: 14 August, 2002
Treatment: NA
Dosage: TABLET;ORAL
4
Denmark
4
Japan
3
United States
2
Croatia
2
Spain
2
Austria
2
Portugal
2
Germany
2
China
2
European Union
1
Colombia
1
Iceland
1
Australia
1
EA
1
Israel
1
Egypt
1
Korea, Republic of
1
Canada
1
Yugoslavia
1
New Zealand
1
Uruguay
1
Tunisia
1
Peru
1
Malaysia
1
ME
1
Bulgaria
1
Ukraine
1
Poland
1
Morocco
1
Norway
1
Hong Kong
1
Slovenia
1
Mexico
1
Argentina
1
Brazil
1
South Africa
1
Hungary
1
Turkey
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic